This drug has now been licensed for use in the UK, it does NOT however necessarily mean that everyone will have free access, I'm sure that NICE will eventually make a judgement on it's usefuleness and what NICE says will have an influence on whether NHS trusts will fund the drug or not.
It has a considerably higher cost than Imatinib (Glivec)but obviously must have a place in treatment of cml where other drugs have failed - this is what the drug is licensed for in the uk.
Glivec 400mg daily costs about £1600 per month, where as Sprycel costs at average dose are over £2000 per month.
There are major debates at present over which drugs are going to be funded by the NHS (witness the recent uproar over Herceptin for breast cancer), so it may be a wait for anyone looking to be prescribed the drug.
Paul